Free Trial
→ Cigar Lake Flooded Again Uranium Supply Shock Repeats (From Digest Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CureVac N.V. stock logo
CVAC
CureVac
$4.66
$4.66
$3.13
▼
$5.72
$1.05B1.77992,546 shsN/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$15.50
$15.51
$9.20
▼
$15.73
$1.82B0.972.20 million shsN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$80.84
-2.4%		$71.36
$1.16
▼
$14.10
$3.50B-0.12189,291 shs684,975 shs
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.42
$17.42
$14.50
▼
$19.92
$424.04M1.1518,480 shsN/A
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CureVac N.V. stock logo
CVAC
CureVac
0.00%0.00%0.00%0.00%-12.73%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.00%0.00%0.00%0.00%+51.07%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00%+8.50%+25.31%+5.94%-6.24%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%0.00%0.00%0.00%-0.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CureVac N.V. stock logo
CVAC
CureVac
$4.66
$4.66
$3.13
▼
$5.72
$1.05B1.77992,546 shsN/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$15.50
$15.51
$9.20
▼
$15.73
$1.82B0.972.20 million shsN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$80.84
-2.4%		$71.36
$1.16
▼
$14.10
$3.50B-0.12189,291 shs684,975 shs
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.42
$17.42
$14.50
▼
$19.92
$424.04M1.1518,480 shsN/A
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CureVac N.V. stock logo
CVAC
CureVac
0.00%0.00%0.00%0.00%-12.73%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.00%0.00%0.00%0.00%+51.07%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00%+8.50%+25.31%+5.94%-6.24%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%0.00%0.00%0.00%-0.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CureVac N.V. stock logo
CVAC
CureVac
1.00
SellN/AN/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
1.50
ReduceN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CureVac N.V. stock logo
CVAC
CureVac
$70.74M14.78$0.99 per share4.73$3.36 per share1.39
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$330.51M5.51$0.16 per share97.88$4.54 per share3.41
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.66M91.01N/AN/A$12.65 per share1.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.726.47N/AN/A199.92%-23.03%-19.09%N/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$27.31M-$0.37N/A31.63N/A-13.13%7.18%4.08%N/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
-$109.74MN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
N/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CureVac N.V. stock logo
CVAC
CureVac
0.03
3.70
3.69
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.41
7.62
6.94
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
6.59
6.59

Institutional Ownership

CompanyInstitutional Ownership
CureVac N.V. stock logo
CVAC
CureVac
17.26%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
96.96%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%

Insider Ownership

CompanyInsider Ownership
CureVac N.V. stock logo
CVAC
CureVac
2.15%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.98%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
12.90%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
CureVac N.V. stock logo
CVAC
CureVac
880224.34 million219.52 millionNo Data
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
350117.43 million113.93 millionOptionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.34 million23.05 millionNot Optionable

Recent News About These Companies

PureTech (LSE:PRTC) Faces a Key ESMO Test Beyond FTSE 100
October 22, 2026  |  kalkinemedia.comK
PRTC's Gallop to Present Ph1b LYT-200 Data at ESMO
October 19, 2026  |  markets.ft.comhttps://markets.ft.com/data/announce/detail?dockey=1323-17840843-42RH34FCF1O3SKBJB1L9PURMBT
PRTC's SPTX Presents Phase 1 GlyphAgo Data at ECNP
October 11, 2026  |  markets.ft.comhttps://markets.ft.com/data/announce/detail?dockey=1323-17829716-0CUU5FEUR7QDRLCTDEKMEHQBS6
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of ...
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/puretech-founded-entity-seaport-therapeutics-170000247.html
Tang Capital Management Boosts PureTech Health (PRTC) Stake to 7.08% After Recent Share Purchase
September 27, 2026  |  kalkinemedia.comK
PureTech Health tries a lower-risk model
September 22, 2026  |  investorschronicle.co.ukhttps://www.investorschronicle.co.uk/content/b84f10c7-b674-47e5-a4e7-12c7eddbf78c
PureTech Health (PRTC) Rises After FDA Fast Track for Blood-Cancer Drug LYT-200
September 21, 2026  |  asktraders.comA
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R ...
September 21, 2026  |  streetinsider.comhttps://www.streetinsider.com/Business+Wire/PureTech+Announces+Successful+End-of-Phase+1+Meeting+with+U.S.+Food+and+Drug+Administration+%28FDA%29+and+Receipt+of+Fast+Track+Designation+for+LYT-200+in+RelapsedRefractory+%28RR%29+High-Risk+Myelodysplast/27082098.html
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis ...
July 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/puretech-founded-entity-celea-therapeutics-060000287.html
PureTech Subsidiary Celea Begins Phase 3 IPF Study Comparing Deupirfenidone With Standard Therapy (PRTC)
July 13, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/puretech-subsidiary-celea-begins-phase-071627519.html
PureTech entity Celea raises $180 million to move lung disease drug into late stage trial
July 2, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/puretech-entity-celea-raises-180-million-move-lung-disease-drug-into-late-stage-2026-07-02/
PureTech Health plc American Depositary Shares (PRTC) Real-Time
July 1, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/prtc/real-time
2 UK shares tipped to more than double my money in 2026!
June 20, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/2-uk-shares-tipped-more-063100674.html
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
June 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/puretech-founded-entity-seaport-therapeutics-060000179.html
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
May 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260513421721/en/puretech-to-showcase-deupirfenidone-program-at-the-american-thoracic-society-international-conference/
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
May 1, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1091582?snapi
PureTech Announces Annual Results for Year Ended December 31, 2025
April 29, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260428142968/en/puretech-announces-annual-results-for-year-ended-december-31-2025/
PureTech Health: Notice of Results
April 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260412617965/en/puretech-health-notice-of-results/
PureTech Gains on Results
April 2, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23028/PureTech-Gains-on-Results
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
April 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260401875786/en/puretech-announces-publication-of-phase-2b-elevate-ipf-trial-results-in-the-american-journal-of-respiratory-and-critical-care-medicine/

New MarketBeat Followers Over Time

Media Sentiment Over Time

CureVac stock logo

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)
As of 10/30/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Dynavax Technologies stock logo

Dynavax Technologies NASDAQ:DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$80.84 -2.00 (-2.41%)
As of 10/30/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)
As of 10/30/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas